Serum Brain-Derived Neurotrophic Factors in Taiwanese Patients with Drug-Naïve First-Episode Major Depressive Disorder: Effects of Antidepressants

Chiou, Yu‐Jie; Huang, Tiao‐Lai

doi:10.1093/ijnp/pyw096

Cited by 24 publications

(32 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other studies demonstrated that antidepressant treatment increased central BDNF levels in animals ( 12 ) as well as peripheral BDNF levels in humans ( 10 , 20 – 22 ). However, these finding are inconsistent, at least in humans, as other studies have shown decreases of peripheral BDNF levels during the course of treatment as well ( 23 ), no change at all ( 24 ) or differences between antidepressants ( 25 ). An especially interesting biological marker for therapy response prediction may be BDNF exon IV promoter methylation which has gained high interest in recent years, as it was shown that especially this promoter site controls BDNF expression ( 26 ).…”

Section: Introductionmentioning

confidence: 94%

BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response

et al. 2018

View full text Add to dashboard Cite

Major problems of current antidepressant pharmacotherapy are insufficient response rates and difficulties in response prediction. We recently provided preliminary evidence in a small study that patients with major depressive disorder (MDD) with a hypomethylation of the CpG-87 site of the promoter IV region of the brain-derived neurotrophic factor (BDNF) gene are less likely to benefit from antidepressants. Here, we aimed at replicating this finding in a secondary analysis of 561 MDD patients (mean age 40.0 ± 11.9 years, 56% female) included into the Early Medication Change study (EMC). We measured BDNF exon IV promoter and p11 gene methylation at Baseline (BL) as well as BDNF-plasma-levels (pBDNF) at BL and day 14 and related them to treatment outcome. Although we were not able to replicate the predictor function of hypomethylation of the BDNF exon IV promoter, a subgroup of patients with severe depression (Hamilton Depression Rating Scale [HAMD-17] ≥ 25) (n = 199) and hypermethylation at CpG-87 of the BDNF exon IV promoter had significantly higher remission rates than patients without a methylation (p = 0.032). We also found that 421 (75%) of 561 patients showed an early improvement (≥ 20% HAMD-17 reduction after 2 weeks), which was associated with a 4.24-fold increased likelihood to remit at study end compared to the 140 patients without early improvement. However, specificity of response prediction of early improvement was low (34%) and false positive rate high (66%). The combination of early improvement with a pBDNF increase between BL and day 14, however, increased the specificity of response prediction from 34 to 76%, and the combination with methylation of the CpG-87 site of the BDNF exon IV promoter from 34 to 62%. Thus, the combined markers reduced false positives rates from 66 to 24% and 38%, respectively. Methylation at other sites or p11 promoter methylation failed to increase specificity of early improvement prediction. In sum, the results add to previous findings that BDNF, BDNF promoter methylation and the combination of clinical and biological markers may be interesting candidates for therapy response prediction which has to be confirmed in further studies.Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT00974155, identifier: NCT00974155

show abstract

Section: Introductionmentioning

confidence: 94%

BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In contrast, decreased BDNF and its receptor tropomyosin-related kinase B (TrkB) contribute to cognitive decline in aging [ 55 , 56 ]. The levels of serum BDNF in patients with drug-naïve first episode depressive disorder were significantly lower as compared to healthy controls [ 57 ]. Reduced protein and mRNA levels of BDNF were found in the hippocampus of postmortem AD samples and MCI patients, [ 58 – 60 ].…”

Section: Introductionmentioning

confidence: 99%

“…Postmortem studies reported that BDNF expression is lower in AD patients [ 57 , 101 ]. Infusion of amyloid fibrils significantly increased HDAC2 expression and its occupancy in the promoter region of Bdnf exon IV, resulting in histone H3 deacetylation and the suppression of BDNF expression [ 102 , 103 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of social relationships on Alzheimer’s memory impairment: mechanistic studies

2018

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is characterized by progressive memory and neuronal loss culminating in cognitive impairment that not only affects a person’s living ability but also becomes a society’s as well as a family’s economic burden. AD is the most common form of dementia in older persons. It is expected that the number of people with AD dementia will increase dramatically in the next 30 years, projecting to 75 million in 2030 and 131.5 million in 2050 worldwide. So far, no sufficient evidence is available to support that any medicine is able to prevent or reverse the progression of the disease. Early studies have shown that social environment, particularly social relationships, can affect one’s behavior and mental health. A study analyzing the correlation between loneliness and risk of developing AD revealed that lonely persons had higher risk of AD compared with persons who were not lonely. On the other hand, it has been reported that we can prevent cognitive decline and delay the onset of AD if we keep mentally active and frequently participate in social activities. In this review, we focus on the impact of social behaviors on the progression of cognitive deficit in animal models of AD with a particular emphasis on a mechanistic scheme that explains how social isolation exacerbates cognitive impairment and how social interaction with conspecifics rescues AD patients’ memory deficit.

show abstract

“…Depressive mood was accompanied by several physiological changes 10 . In the present study, we focused on the possible changes in cortisol and neurotrophins levels, and this biomarker relation with depression and ostomy 11,12 . This marker relationship in ostomy patients is still poorly described.…”

Section: Introductionmentioning

confidence: 99%

Depressive symptoms and neurotrophin levels in ostomy patients

Bavaresco

Schwalm

Jornada

et al. 2018

J. bras. psiquiatr.

View full text Add to dashboard Cite

Objective: The aim of the present study was to investigate the depressive symptoms and changes in neurotrophins (BDNF, NGF, NT-3), and cortisol levels in serum of peripheral blood from ostomy patients compared to healthy control group. Methods: We evaluated ostomy (n = 29) and healthy control (n = 30) patients. The neurotrophin (BDNF, NGF, NT-3), and cortisol levels were assessed by ELISA in serum of peripheral blood. Depressive symptoms were defined based on the Hamilton Depression Rating Scale (HDRS), and major depression disorder was based on clinical interviews and was confirmed with the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Results: The results showed a significant decrease in BDNF levels and, a significant increase in NT-3 levels in serum of peripheral blood from ostomy patients when compared to healthy controls. The levels of NGF and cortisol showed no significant differences between groups. The depressive symptom evaluations by HDRS demonstrated a significant increase in ostomy patients when compared to healthy controls. The major depression disorder diagnosis by SCID-I showed no significant difference between groups. Conclusion: Our results suggest ostomy triggers significant depressive symptoms and alterations in neurotrophins levels in serum of peripheral blood samples collected from these patients.

show abstract

Serum Brain-Derived Neurotrophic Factors in Taiwanese Patients with Drug-Naïve First-Episode Major Depressive Disorder: Effects of Antidepressants

Cited by 24 publications

References 31 publications

BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response

BDNF Plasma Levels and BDNF Exon IV Promoter Methylation as Predictors for Antidepressant Treatment Response

Impact of social relationships on Alzheimer’s memory impairment: mechanistic studies

Depressive symptoms and neurotrophin levels in ostomy patients

Contact Info

Product

Resources

About